395 A first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, in patients with advanced cancer and resistance to PD-(L)1 therapy
暂无分享,去创建一个
P. LoRusso | S. Hu-Lieskovan | K. Papadopoulos | T. Yap | J. Holz | D. Wong | D. Gliddon | U. Grabowska | Michelle Morrow